Novartis And BioAge Team Up To Develop Aging Therapies And Boost Investor PotentialSeeking Alpha • 01/13/25
Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMAGlobeNewsWire • 12/30/24
Novartis must face claims it paid kickbacks to promote MS drug, US appeals court rulesReuters • 12/27/24
Buy 5 Large-Cap Laggards of 2024 Likely to Surge in the Near TermZacks Investment Research • 12/23/24
The Zacks Analyst Blog Mastercard, The Procter & Gamble, Novartis AG, IDT and GSI TechnologyZacks Investment Research • 12/13/24
Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancerGlobeNewsWire • 12/10/24
Novartis Announces Positive Results From Late-Stage Study on FabhaltaZacks Investment Research • 12/09/24
Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CMLGlobeNewsWire • 12/08/24